Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sanara MedTechSMTI +0.55%80 Debt-to-Equity is 6.11 as of Jun. 2026, which is 7538% above its 10-year median of 0.08. GuruFocus rates SMTI with a GF Score™ of 80/100 and a GF Value™ of $43.37 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 699 Medical Devices & Instruments companies, Sanara MedTech ranks worse than 98.57% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Sanara MedTech's Debt-to-Equity or its related term are showing as below:
SMTI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -7.87 Med: 0.08 Max: 11.65
Current: 6.11
During the past 13 years, the highest Debt-to-Equity Ratio of Sanara MedTech was 11.65. The lowest was -7.87. And the median was 0.08.
SMTI's Debt-to-Equity is ranked worse than 98.57% of 699
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs SMTI: 6.11
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Sanara MedTech Debt-to-Equity Related Terms
Sanara MedTech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Sanara MedTech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMTI vs UTMD, OSUR, EMBC: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Sanara MedTech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sanara MedTech Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sanara MedTech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Sanara MedTech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sanara MedTech (SMTI) has a Debt-to-Equity of 6.11 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sanara MedTech and its competitors. This is 7538% above median its historical median of 0.08. According to the industry distribution chart, Sanara MedTech ranks #689 out of 699 companies in the Medical Devices & Instruments industry, placing it in the top 98.6%.
Is Sanara MedTech's Debt-to-Equity too high?
Sanara MedTech's current Debt-to-Equity of 6.11 is 7538% above median its 10-year median of 0.08. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Sanara MedTech's value of 6.11 is 2556.5% above this industry median. Based on the distribution chart, Sanara MedTech ranks #689 out of 699 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sanara MedTech has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's Debt-to-Equity compare to UTMD and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Sanara MedTech ranks #689 out of 699 companies for Debt-to-Equity. This places Sanara MedTech in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Sanara MedTech's value of 6.11 is 2556.5% above this benchmark. While the company's 10-year median is 0.08 vs. the industry median of 0.23, Sanara MedTech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sanara MedTech's current Debt-to-Equity of 6.11 is 2556.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Sanara MedTech and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sanara MedTech's current Debt-to-Equity is 6.11, which is 7538% above median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Modestly Undervalued. The stock's GF Value™ is $43.37, compared to a current price of $34.45 — trading 20.6% below its estimated fair value. The current Debt-to-Equity is 6.11, which is 7538% above median its 10-year median of 0.08 and 2556.5% above the Medical Devices & Instruments industry median of 0.23. Sanara MedTech's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current Debt-to-Equity is 6.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sanara MedTech (SMTI) Overvalued in 2026?
Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued.
The current stock price of $34.45 is trading 20.6% below its estimated GF Value™ of $43.37.
GuruFocus considers Sanara MedTech to be Modestly Undervalued.
Key valuation signals for SMTI:
Debt-to-Equity: 6.11 (7538% above median its 10-year median of 0.08)
GF Value™: $43.37 vs. price of $34.45 (20.6% below fair value)
Industry Position: 2556.5% above the Medical Devices & Instruments median (#689 of 699)
No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
80GF Score
Get the complete analysis for SMTI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SMTI has been successfully added to your 
